SIA
1.8.2016 16:01:36 CEST | Business Wire | Press release
ČSOB , one of the largest commercial banks in the Czech Republic and part of the Belgian KBC Group , and SIA , a company specializing in the management of electronic payments, have developed and launched the first mobile wallet for NFC payments in the Czech Republic that supports both the MasterCard and VISA circuits.
The new mobile application “NaNákupy” enables ČSOB clients to make contactless payments to retailers by smartphone. Thanks to SIA’s infrastructure, debit and credit cards can be virtualized in the mobile wallet through Host Card Emulation (HCE) technology that stores data in total security, regardless of the mobile operator and without the need to apply for a new card or a special SIM card.
By the end of 2016, NaNákupy app users will have the possibility to pay
on the Internet
, easily manage the settings of different credit
cards
and constantly monitor transactions
made via mobile.
In
addition, it will be possible to virtualize loyalty cards
and store
receipts,
or share shopping lists on a smartphone
.
The
mobile wallet will also send notifications on goods warranty or
insurance expiration dates
. All of the functions will be available
even to other banks’ clients who download the app to their mobile device.
“The ČSOB NaNákupy application will be the first in the Czech Republic to offer its users mobile telephone payments to retailers regardless of whether they hold a MasterCard or VISA,” says Petr Hutla, member of the ČSOB Board of Directors in charge of Retail . “We aim to simplify our clients’ lives, and therefore we decided to launch a solution where downloading the application and activating the service is enough,” explains Mr. Hutla.
“The Czech Republic has the highest proportion of retail NFC transactions in Europe and, therefore, is the ideal place for mobile payments. We are proud to have our long lasting relationship with ČSOB extended by the innovative mobile payment solution we have launched together,” comments Nicola Cordone, Senior Vice President SIA .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005628/en/
Contact:
SIA
Filippo Fantasia / Valentina Piana, Tel. +39
02.6084.2833/2334
pressoffice@sia.eu
or
ČSOB
Martina
Slavíková, Phone +420 603.800.664
martslavikova@csob.cz
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme19.2.2026 13:00:00 CET | Press release
With preloaded global maps, intelligent route tools, and weeks-long battery life, the T-Rex Ultra 2 is made for those who seek boundaries only to push beyond Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/ Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme “With the T-Rex Ultra 2, we
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 12:00:00 CET | Press release
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal rangeSingle dose of YOLT-202 was well tolerated with a favorable safety profile YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as
Infobip Recognized as RCS for Business Leader by Juniper Research19.2.2026 11:15:00 CET | Press release
Recognition comes as Infobip celebrates its 20th anniversary Global cloud communications platform Infobip has been named the number one Established Leader in the Juniper Research RCS for Business 2026 Leaderboard. The analyst firm scored Infobip as the top vendor out of 17 because of its superior capability and capacity, enhanced product and position and significant market presence. Juniper Research scores vendors on a range of factors including but not limited to their geographical reach, depth of partnerships, RCS value-added services, notable RCS deployments, and innovation. According to Juniper Research, Infobip stands out for its wide network of mobile operator connections for RCS for Business and its extensive geographic reach, including being the first provider to launch RCS messaging across all major US telecom carriers. Brands such as Virgin Atlantic are using Infobip’s RCS solutions to deliver interactive, conversational messaging that drives stronger customer engagement. Mol
Serviceplan Group Deploys Creative AI Across Global Operations in Partnership With Luma AI19.2.2026 11:00:00 CET | Press release
Serviceplan Group becomes the first of the world’s largest agency groups to standardize AI for creative work across professional workflows at scale, strengthening productivity and long-term competitiveness. Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219346568/en/ Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. Shown here (L-R) Alex Schill, Global Chief Creative Officer of Serviceplan Group, Jason Day, Head of EMEA for Luma AI, Amit Jain, Co-Founder and CEO of Luma AI, and Florian Haller, CEO of Serviceplan Group. Under the agreement, Luma AI will serve as Serviceplan Group’s AI technology partner, embedding AI for creative work into professional workflows spanning strategy, cr
GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 10:59:00 CET | Press release
GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom